INTRODUCTION
Hypertension is associated with increased arterial contractility and resistance to receptormediated vasodilators. Kv7 channels (Kv7.1 -Kv7.5) are voltage-gated potassium (K + ) channels encoded by KCNQ genes that regulate the contractile state of vascular smooth muscle at rest and contribute markedly to receptor-mediated vasorelaxations 1, 2 . Arterial smooth muscle cells express Kv7.1, Kv7.4 and Kv7.5, with negligible Kv7.2 and Kv7.3 levels 3 , and blockers of these channels such as XE991 or linopirdine can contract most arteries or enhance vasoconstrictor responses [4] [5] [6] [7] . Conversely, agents that enhance Kv7 activity are effective vasorelaxants 4-6, 8, 9 . In addition, Kv7 blockers, as well as knockdown of Kv7.4 impairs vasorelaxations produced by receptor agonists in various arteries 2, 10, 11 . Notably, many receptor-mediated vasorelaxations are impaired in arteries from hypertensive animals, and any remaining relaxation is no longer sensitive to Kv7 blockade 10, 12, 13 . The functional impairment is linked to a reduction of Kv7.4 protein abundance in renal, mesenteric and coronary arteries from hypertensive animals, which is not correlated with a reduction in gene transcript (KCNQ4), suggesting the involvement of post transcriptional mechanisms. Whilst some molecular determinants of the pathological changes in Kv7 channel expression occurring in the vasculature during hypertension have started to be unveiled 14, 15 , the mechanisms that dictate the membrane abundance of Kv7.4 channels in smooth muscle are yet to be fully elucidated. K + channel trafficking can be regulated by several processes, such as the protein internalization/endosomal recycling pathway 16 , and altered protein folding via changes in the interaction with molecular chaperones such as Heat Shock Proteins (HSPs) 17 . Here, we aim to uncover the processes governing the handling of Kv7.4 in vascular smooth muscle following treatment with Angiotensin II (Ang II), a molecule strongly associated with cardiovascular dysfunction, to gain insight into the processes that control Kv7.4 membrane abundance during hypertension.
METHODS
Detailed methods are available in the Online Supplement (http://hyper.ahajournals.org). The authors declare that all supporting data are available within the article (and its online supplementary files).
Animals
All experiments were performed in accordance with the UK Animals (Scientific Procedures) Act (1986) and were approved by the local ethics committees. 10-12 weeks-old male Wistar rats (Charles River, U.K.) and C57BL/6J mice (12-18 weeks of age) were killed by cervical dislocation.
Statistical analysis
All data are expressed as mean ± s.e.m. One-or two-way ANOVA test followed by a Dunnett's or Tukey's multiple comparisons test, and Student's t-test (paired or unpaired) were used to determine statistical significance between groups, according to the different experiments.
Differences were considered statistically significant when p<0.05.
RESULTS

Effects of Ang II on Kv7.4 levels and function
We first investigated the effects of Ang II on gross Kv7.4 levels in protein lysates from whole mesenteric arteries. Western blot experiments showed that 100nmol/L Ang II reduced Kv7.4 protein levels by ∼50% after 1h compared to control vessels, by ~70% after 3h, and by ∼80% after 7h treatment (Fig 1A) . Incubation with Ang II did not reduce KCNQ4 mRNA levels even after 7h (Fig 1B) , suggesting a post-transcriptional mechanism. Similar results were also observed in rat aorta (Fig S1A-B , http://hyper.ahajournals.org). To circumvent any possible non-specific binding of the Kv7.4 antibody we investigated the effects of Ang II treatment on a human smooth muscle cell line (SGVSM-9) transfected with EGFP-tagged Kv7.4, using an anti-GFP antibody. In SGVSM-9 cells transfected with EGFP-Kv7.4, in-cell western blot experiments showed that treatment for 1h with 100nmol/L Ang II induced a ~20% decrease in EGFP-Kv7.4 with respect to control cells (Fig 1C) . Moreover, in CHO cells expressing the angiotensin II receptor type 1 (AT1R) and EGFP-Kv7. 4 Incubation of 100nmol/L Ang II for 3h decreased the amplitude of XE991-sensitive current by about 60% (Fig 1D) . ML213 is an activator of Kv7.2, Kv7.4 and Kv7.5 channels that has been characterized in several smooth muscles, including VSMCs from mesenteric arteries 18 . In sharp microelectrode studies on whole mesenteric arteries ML213 hyperpolarized the membrane potential by approximately 17mV; a subsequent application of the KATP channel activator levcromakalin (10µmol/L) further reduced membrane resting potential (Fig 1E and Fig S2B, http://hyper.ahajournals.org, control). Treatment with Ang II for 2h blunted ML213-induced hyperpolarization (reduction of membrane potential by ~2mV) but did not affect the membrane hyperpolarization caused by levcromakalin (Fig 1E and Fig S2B, . Incubation of mesenteric arteries with Ang II impaired the relaxation of pre-contracted mesenteric arteries produced by ML213 (Fig 1F and S2D, Fig S3, concomitant with a decrease in the global level of Kv7.4 (Fig 2A) . Fluorescence-intensity profiles along cross-sections of VSMCs showed that in control cells the Kv7.4 signal was higher in the membrane than cytosol (membrane:cytoplasm ratio 1.57±0.12), while in Ang II treated cells Kv7.4 fluorescence was similar between the two regions (membrane:cytoplasm ratio 0.88±0.10) (Fig 2B) .
Role of endosomal and proteasomal pathways in Ang II-mediated Kv7. 4 
degradation
To gain insight about the cellular mechanisms that mediated the shift in Kv7.4 localization and reduction in total protein levels, mesenteric arteries were incubated with the endosome inhibitor dynasore or the proteasome inhibitor MG132 in presence or absence of Ang II. In Western blot experiments co-incubation of dynasore (DYN), used at concentrations (100μmol/L) shown to be effective in previous studies 19 , did not fully prevent the reduction of Kv7.4 produced by 3h incubation with Ang II (Fig. 2C) . Conversely, MG132 (20 µmol/L) fully prevented the Ang II-induced reduction of Kv7.4 (Fig. 2C) . MG132 also counteracted the impairment of ML213-induced relaxation of mesenteric arteries by Ang II in myography experiments (Fig 2D) .
Role of oxidative stress in Ang II-induced Kv7.4 degradation Ang II is known to increase oxidative stress 20 which induces proteasome-mediated protein degradation 21 . We therefore evaluated whether the observed increase of Kv7.4 protein degradation induced by Ang II was mediated by oxidative stress. In VSMCs, treatment with Ang II for 30min increased the production of reactive oxygen species (ROS) measured by the fluorescence dye ROS Deep Red (by ~50% compared to time-matched control), similarly to that caused by 1mmol/L H2O2 (increase by ~70%, Fig 3A) . In contrast, longer incubation (3h) with Ang II did not significantly enhance ROS levels with respect to time-matched control, whereas H2O2 was still able to increase ROS levels (by ~40%, (Fig 3A) . The ROS scavenger
http://hyper.ahajournals.org), but did not prevent either Kv7.4 protein down-regulation (Fig 3B) or the impairment of ML213-induced relaxation in mesenteric arteries when co-incubated with Ang II (Fig 3C) . (Fig 4A) . In contrast, a significant reduction (by ~40%) in Kv7.4:HSP90 interactions was detected in VSMCs upon incubation with Ang II (Fig 4B) . HSP70/90 machinery is linked to the proteasome system via the co-chaperone and E3 ubiquitin-ligase CHIP (C-terminus of Hsp70-Interacting Protein). Incubation of VSMCs with Ang II enhanced the interaction of Kv7.4 with CHIP by ~30% (Fig 4C) , and increased the number of ubiquitin molecules interacting with Kv7.4 by ~65% when compared to control (Fig 4D) . These data suggested that Ang II reduced Kv7.4:HSP90 interactions thus enhancing protein ubiquitination via an increased interaction of Kv7.4:HSP70 complex with CHIP. To corroborate this, we studied the effect of 17-AAG (17-Demethoxy-17-(2-propenylamino) geldanamycin), a geldanamycin-analog which inhibits HSP90 function, on total Kv7.4 protein levels. Incubation of mesenteric arteries with 1µmol/L 17-AAG caused a reduction of Kv7.4 protein by ∼60% (Fig 5A) , increased the number of interactions between Kv7.4 and CHIP (Fig 5B) , and the number of ubiquitin molecules interacting with Kv7.4 ( Fig 5C) .
Role of HSPs in
Role of HSPs-CHIP-ubiquitin system in Kv7. 4 
degradation in vivo
Since Kv7.4 protein is down-regulated in Ang II-infused mice 8 , we investigated whether the observed alterations of HSPs-CHIP-ubiquitin system could be detected in the same in vivo model of prolonged exposure to Ang II. PLAs showed that the number of interactions of Kv7.4 with HSP70 in VSMCs isolated from mesenteric arteries of Ang II-infused mice was not significantly different from those isolated from saline-infused mice (Fig 6A) , whereas a significant decrease in the number of Kv7.4:HSP90 interactions was observed in VSMCs from Ang II-with respect to saline-infused mice (Fig 6B) . Moreover, an increased interaction of Kv7.4 with CHIP ( Fig 6C) and ubiquitin (Fig 6D) was detected in VSMCs from Ang II-mice when compared to control groups. , but one study suggested that it also enhances the current mediated by Kv7.5 26 , which contributes with Kv7.4 to the formation of the mature channel in the vasculature 1, 27 . Due to the lack of Kv7 subunit-specific blockers, we could not rule out the involvement of Kv7.5 in ML213-induced relaxation. However, our immunofluorescence data ( Fig S4, http: //hyper.ahajournals.org) together with previous evidence 2, 10, 11, 27 infer that the reduction of vasorelaxant effects of ML213 prompted by Ang II was mediated by decreased Kv7.4 levels in VSMCs. Interestingly, ML213 still produced some relaxation in Ang II even though its ability to hyperpolarize was largely lost by incubation with Ang II. A previous study revealed that 1 µM ML213 produced considerable relaxation of pre-contracted arteries without marked membrane hyperpolarization. In both Jepps et al and present work any relaxation was abrogated by pre-incubation with Kv7 blockers showing that Kv7 channel involvement. This apparent discrepancy in electro-mechanical coupling probably reflects the differences in experimental conditions as isometric tension studies involved a pre-contracted and therefore depolarized artery compared to the microelectrode recordings performed on unstimulated arteries. Like other Kv7.2-7.5 activators ML213 works through stabilization of the open configuration that will be more apparent under depolarized conditions. However, further investigation regarding the role of Kv7 channels in regulating the electro-mechanical coupling in VSMCs is required. Ang II affects protein folding in hypertensive mice 31 , regulates the activity of HSPs, which mediate some maladaptive responses occurring in hypertension [32] [33] [34] , and also regulate ion channel folding. HSP90 in particular, plays a pivotal role in the folding of the cystic fibrosis transmembrane conductance regulator (CFTR), the ClC-2 chloride channel 35 , HERG channel 17, 36 and the KATP potassium channel 37 . Moreover, enhancement of the HERG:HSP90 interaction is responsible for the increased membrane trafficking induced by estradiol 38 . Reduced binding of HSP90 decreases the interaction of client proteins with the HSP40-HSP70-HOP chaperone pathway that promotes forward trafficking, and increases interaction with HSP70-ubiquitin ligase CHIP complexes, which lead to proteasome-mediated degradation 39 . Our data reveal that the molecular chaperones HSP70/90 interact with Kv7.4 in native VSMCs, and that Ang II treatment selectively reduced the interaction of Kv7.4 with HSP90 in this physiological environment. In heterologous expression systems, modulating HSP90 isoforms levels either by overexpression or silencing strategies revealed a differential role in Kv7.4 maturation of the two major HSP90 isoforms, namely α and β, with β-isoform promoting protein folding, and α-isoform enhancing CHIP-mediated proteasomal degradation 40 . Although some distinctive features exist, HSP90 isoforms exert similar actions, with many functions being characteristic of both isoforms and only associated more frequently to one of them 41 . Moreover, their expression is differentially regulated, with a constitutive form (HSP90β) and an inducible one (HSP90α). Although we did not investigate the contribution of α-or β-isoform, in our experiments we did not observe any change in HSP90 levels, suggesting that HSP90 expression was not modified by Ang II incubation, and that a different mechanism was responsible for the alteration in Kv7.4:HSP90 binding. Covalent modifications, including phosphorylation, acetylation and nitrosylation, influence the activity of HSP90 and consequently the maturation of selected clients 42 . Phosphorylation and acetylation slow down HSP90 activity, resulting in a reduced maturation of client proteins [43] [44] [45] . Therefore, Ang II might activate different pathways ultimately altering HSP90 and/or Kv7.4, modifying their ability to interact. Irrespective of the molecular mechanism, the ultimate effect was an increased interaction of Kv7. .
PERSPECTIVES
We show for the first time in vascular smooth muscle that Ang II enhances Kv7.4 degradation via the ubiquitin-proteasome system, through a reduced interaction with HSP90. The specific pathway(s) activated by Ang II, as well as the possible molecular modifications occurring in all the interactors (including additional co-chaperones) will need to be further investigated.
Indeed, Ang II can activate diverse intracellular pathways, including non G-protein signaling, and modulate several processes, such as inflammation 20 , which might in turn regulate HSPs activity and therefore protein stability and degradation. However, the present study has identified a novel and dynamic regulation of Kv7.4 that impacts considerably on vascular physiology. Noticeably, we showed that these alterations also occur in vivo after chronic exposure to Ang II, a well-known model of hypertension where Kv7.4 expression and function is reduced 8 , suggesting that the observed reduction of Kv7.4 protein stability and enhanced degradation play a role also in the pathological changes occurring in hypertension. Since modulators of HSP90 function are being developed therapeutically [47] [48] [49] [50] , these data provide a possible new therapeutic strategy for the treatment of hypertension. 
